Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078237 | SCV000110075 | uncertain significance | not provided | 2015-09-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000818066 | SCV000958661 | uncertain significance | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 8 of the GALT gene. It does not directly change the encoded amino acid sequence of the GALT protein. It affects a nucleotide within the consensus splice site of the intron. This variant is present in population databases (rs398123186, ExAC 0.01%). This variant has been observed in individual(s) with clinical features of GALT-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 92523). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001271246 | SCV001452290 | uncertain significance | Galactosemia | 2020-09-16 | no assertion criteria provided | clinical testing |